Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034

The global drug discovery platforms market size is calculated at USD 211.26 million in 2025 and is expected to reach around USD 635.45 million by 2034, growing at a CAGR of 13.44% for the forecasted period.

Ottawa, July 30, 2025 (GLOBE NEWSWIRE) -- The global drug discovery platforms market size was valued at USD 186.24 million in 2024 and is predicted to hit around USD 635.45 million by 2034, a study published by Towards Healthcare a sister firm of Precedence Research.

The growth of the market is driven by the growing investments in research and development, and integration of AI and ML with technological advancements further drives the growth of the market.

Get a free sample of the Drug Discovery Platforms Market report to preview key insights and trends: https://www.towardshealthcare.com/download-sample/5539

Key Takeaways

North America dominated the global drug discovery platforms market in 2024.
Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
By type of display library technology, the phage display segment held a dominant presence in the market in 2024.
By type of display library technology, the yeast display segment is anticipated to grow at the fastest rate in the market during the studied years.
By type of molecule, the antibodies segment dominated and was observed to sustain the dominance over the forecast period.

Drug Discovery Platforms Market Overview & Potential

Drug discovery platforms are integrated systems designed to streamline and speed up the process of finding, developing, and refining potential drug candidates. They utilize technologies such as artificial intelligence (AI), high-throughput screening, and automation to identify promising targets and molecules. These platforms aim to enhance efficiency, cut costs, and accelerate drug development compared to traditional methods. They are transforming the pharmaceutical industry by speeding up the creation of new, effective medicines. By integrating advanced technologies and simplifying the discovery process, these platforms are set to play a vital role in future healthcare advancements.

What is the Growth Potential Responsible for the Growth of the Drug Discovery Platforms Market?

The global market for drug discovery platforms is growing rapidly, fueled by several key factors. These include rising rates of chronic and infectious diseases, increasing investment in pharmaceutical and biotech R&D, and technological advances like AI, machine learning, and high-throughput screening. Additionally, the focus on precision medicine and targeted therapies is expanding the market. The use of drug discovery platforms is also broadening beyond traditional pharma research to include biotech, diagnostics, and personalized medicine, further boosting growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What Are the Growing Trends Associated with the Drug Discovery Platforms Market?

AI-powered Drug Discovery:

AI is transforming drug discovery by speeding up research, increasing accuracy, and shortening development timelines. It is used in target identification, molecule design, and optimizing clinical trials.

Cloud-based Platforms:

Cloud computing is becoming essential in drug discovery, offering benefits like streamlined operations, lower costs, and quicker development cycles.

Display Libraries:

Display libraries, especially phage display, are gaining popularity for their ability to enable large-scale, high-throughput screening and increase diversity in lead discovery.

Precision Medicine:

Interest in precision medicine and targeted therapies is growing, with researchers aiming to develop drugs tailored to specific patient groups and disease types.

What Is the Growing Challenge in the Drug Discovery Platforms Market?

The drug discovery platforms market faces hurdles such as rising costs, long development times, and difficulties in accurately modeling disease mechanisms. Other issues include data privacy concerns, cybersecurity threats, and the need for skilled personnel to operate AI-based systems. These factors hinder the growth of the market and limit its expansion of the market. The government support, large patient population, growing CROs, cost effectiveness, strategic partnerships, AI and informatics, visual drug discovery services, and drug repurposing further fuel the growth and expansion of the market in the region.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Regional Analysis

How Did North America Dominate the Drug Discovery Platforms Market in 2024?

North America dominated the global drug discovery platforms market in 2024. The growth of the market in the region is driven by the well-established infrastructure, especially healthcare infrastructure, along with rising investment for research and development by the government, also further fuels the growth of the market in the region. The strong presence of pharmaceutical and biotechnology companies in the region also increases the demand for the market due to growing research for drug discovery and development, which further fuels the growth of the market. The supportive regulatory environment and increased research and development spending by pharmaceutical and biotech companies in the region further fuel the growth of the market in the region.

The U.S. fosters drug discovery platforms market growth through strong academic-industry collaboration, advanced biotech infrastructure, and a robust intellectual property system. Government initiatives and regulatory support encourage innovation. A rich talent pool from leading universities drives research, while access to venture capital enables startups and established firms to advance novel therapies efficiently.

Canada supports drug discovery through significant public funding, academic partnerships, and a collaborative research environment. Institutions emphasize translational medicine and early-stage R&D. Regulatory agencies encourage innovation with progressive frameworks. The country's multicultural population also enables diverse clinical research, strengthening Canada's role in addressing global health challenges through targeted drug development.

What Made the Asia Pacific Significantly Grow in The Drug Discovery Platforms Market In 2024?

Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period. Increased government investments in pharmaceutical research and infrastructure development through government support propel the growth of the market in the region. The rising healthcare expenditure leads to greater demand for advanced healthcare solutions also increases the growth of the market. Asia Pacific is a growing and emerging hub for contract research organizations play a crucial role in outsourcing drug discovery activities by other regions' consumers, driving the growth of the market in the region.

Government reforms, talent repatriation, and investment in life sciences drive China’s expanding drug discovery platforms market. Research parks and biotech hubs across cities like Shanghai promote innovation. Enhanced regulatory processes and incentives for novel drug development have shifted the focus from generics to original therapeutics, boosting domestic pharmaceutical innovation.

India’s growth in drug discovery stems from its vast scientific workforce, cost-effective research capabilities, and strong academic institutions. Government initiatives support innovation through incubators and biotech parks. Rising collaboration between academia and industry fosters early-stage research, while improvements in regulatory frameworks encourage the development of original molecules and targeted therapies.

According to Volza's Global Export data, the World shipped out 248122 Pharmaceutical shipments from November 2023 to October 2024 (TTM). These exports were handled by 7224 global exporters to 12066 buyers, showing a growth rate of 133% over the previous 12 months.
Globally, India, Belgium, and the United States are the top three exporters of pharmaceuticals. India is the global leader in Pharmaceutical exports with 578683 shipments, followed closely by Belgium with 9244 shipments, and the United States in third place with 8465 shipments.

Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By Type of Display Library Technology

The phage display segment held a dominant presence in the drug discovery platforms market in 2024. The phase display is a key technology that is used in drug discovery to isolate and identify the desired molecule, especially proteins and peptides, that bind to the target molecule. The key advantages of phase displays, like high diversity, versatility, and efficiency, further increase the demand for the market. The application in drug discovery, like antibody discovery, peptide therapeutics, target validation, and vaccine development, boosts the growth of the market. The growing key therapeutic applications, like the development of therapeutic antibodies, propel the demand for the market, further contributing to the expansion of the market.

The yeast display segment is anticipated to grow at the fastest rate in the drug discovery platforms market during the studied years. The growth of the market is driven by the growing applications like antibody discovery, enzyme engineering, protein-protein interaction studies, target-based drug discovery, and nanobody discovery increases the demand for the technology, which fuels the growth of the market. The growing advantages and properties offered by the technology, like quantitative analysis, compatibility with FACS, affinity maturation, high throughput screening, and eukaryotic systems, play a crucial role in further propelling the growth and expansion of the market.

By Type Of Molecule

The antibodies segment dominated and was observed to sustain the dominance over the forecast period. The antibodies segment holds a significant share in the drug discovery platform market, driven by the growing use of monoclonal and polyclonal antibodies in targeted therapies. These molecules are widely used in immunotherapy, oncology, and autoimmune disease treatment due to their high specificity and efficacy. Drug discovery platforms support antibody screening, engineering, and optimization, accelerating development timelines. As demand for biologics continues to rise, the adoption of advanced platforms for antibody discovery fuels market growth in this segment.

Recent Developments in the Drug Discovery Platforms Market

In July 2025, Elix and the Life Intelligence Consortium (LINC) announced the commercial launch of an AI-based drug discovery platform that uses federated learning across data from multiple pharmaceutical companies. This marks the first global deployment of such technology.

In March 2025, Boehringer Ingelheim introduced its new comprehensive technology platform on Tuesday, aimed at streamlining data management and processes to accelerate drug development. The One Medicine Platform will replace over 20 outdated systems, creating a unified ecosystem to improve cross-functionality and operational efficiency.

Top Companies and Their Contributions to the Market

Company	Contributions & Offerings
Insilico Medicine	Leverages Pharma.AI - PandaOmics for AI-powered target/biomarker discovery, Chemistry42 for generative molecule design, and InClinico for clinical trial prediction. Has taken its lead pan-fibrotic candidate, INS018_055, from target discovery to Phase II in ~30 months. Demonstrated bioavailable CDK8 inhibitor via AI-driven Chemistry42.
Evotec	Offers end-to-end integrated drug discovery: target ID, screening, medicinal chemistry, biologics manufacturing, and CMC. Partners include Janssen (via TargetAlloMod), Lilly (metabolic/kidney diseases), Novartis, Novo Nordisk, Related Sciences, and more, powering multi-modality pipelines.
Laboratory Corporation of America Holdings (LabCorp)	Provides high-throughput pre-clinical screening, biomarker profiling, ADME/Tox, clinical trial diagnostics, and real-world evidence solutions. Integrates genomics, data analytics, and centralized labs globally to accelerate translational and clinical R&D.
Atomwise	Uses deep learning and structure-based AI (AtomNet) to predict protein–ligand binding, enabling virtual high-throughput screening on millions of compounds, partners with pharma and biotech to identify lead molecules for diverse therapeutic targets.
Merck	Owns Merck Research Labs with integrated in-house platforms including computational chemistry, high-throughput screening, and genomics. It invests in AI collaborations (e.g., with Schrödinger, Cyclica) to bolster target identification and small-molecule discovery.
Pfizer	Builds extensive discovery platforms—HTS, structural biology, chemoinformatics, AI/ML modeling, and phenotypic screening. Active in AI drug discovery partnerships (e.g., XtalPi, DeepMind), and open science efforts for protein structure and drug-target mapping.
Exscientia plc	Pioneers AI-driven end-to-end drug design, advancing candidate molecules into clinical trials faster via Centaur Chemist. Publishes human-dose candidates from AI design, with strategic pharma partnerships and a pipeline in immuno-oncology and cardiometabolic diseases.
Thermo Fisher Scientific	Supplies essential platforms: high-throughput screening systems, mass spectrometry, protein analysis, cell-based assays, informatics software, and reagent kits. Supports discovery across small molecules, biologics, and cell therapies via integrated hardware and software solutions.
Recursion Pharmaceuticals	Combines automated biology (cell imaging) with AI/ML to rapidly characterize disease models and drug effects. Progressed eight AI-designed drug candidates (REC-3565, REC-994, etc.) into clinical trials. Offers Recursion OS, enabling biology-first target discovery.
Eli Lilly and Company	Maintains Lilly Research Labs with integrated capabilities: high-throughput screening, structural biology, computational chemistry, and translational biomarkers. Partners with AI-first firms (e.g., with Evotec, Insilico) to accelerate novel therapeutic target discovery and drug design.

Browse More Insights of Global Drug Discovery & Development

The GLP-1 drugs market is witnessing rapid momentum worldwide, with expectations of generating substantial revenue potentially in the hundreds of millions between 2025 and 2034.

The global immuno-oncology drugs market is on a high-growth trajectory. Valued at US$ 94 billion in 2024, it is projected to reach US$ 109.39 billion in 2025 and soar to approximately US$ 421.27 billion by 2034, growing at a CAGR of 16.34% over the forecast period.

The U.S. drug screening market is steadily growing. From US$ 2.70 billion in 2024 to US$ 2.79 billion in 2025, it’s expected to reach US$ 3.84 billion by 2034, expanding at a CAGR of 3.64%.

The computer-aided drug design (CADD) market is gaining traction globally, with anticipated revenues climbing into the hundreds of millions over the next decade.

The drug discovery SaaS platforms market is evolving fast, expected to generate significant revenue between 2025 and 2034 as digital transformation accelerates across pharma R&D.

The drug discovery as a service market is expanding rapidly from US$ 21.3 billion in 2024 to US$ 24.32 billion in 2025, and is forecasted to reach US$ 79.82 billion by 2034, growing at a CAGR of 14.17%.

The generative AI in drug discovery market is making waves. Valued at US$ 250 million in 2024, it's set to grow to US$ 318.55 million in 2025, and nearly US$ 2.85 billion by 2034, posting an impressive CAGR of 27.42%.

The machine learning in drug discovery market is experiencing a notable surge, with revenues expected to reach several hundred million dollars by 2034, reflecting growing adoption across the pharmaceutical value chain.

Similarly, the AI and ML in drug development market is rapidly expanding worldwide, with strong potential for multimillion-dollar revenues throughout the forecast period.

The sterile drug product testing market is on a growth path driven by rising production of biologics and injectable drugs, making it a key segment to watch from 2024 to 2034.

Drug Discovery Platforms Market Key Players

Insilico Medicine
Evotec
Laboratory Corporation of America Holdings
Atomwise
Merk
Pfizer
Exscientia plc
Thermo Fisher
Recursion Pharmaceuticals
Eli Lilly and Company
Roche

Segments Covered in The Report

By Type of Display Library Technology

Phage display library
Yeast display
Other

By Type of Molecule

Antibodies
Peptides
Other

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Access the complete Drug Discovery Platforms Market report for in-depth analysis, forecasts, and strategic recommendations: https://www.towardshealthcare.com/price/5539

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.